Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

189
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
189
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

138
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
138
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

931
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
931
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

137
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
137

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes.

Nature communications·2025
Same author

Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys.

Haemophilia : the official journal of the World Federation of Hemophilia·2024
Same author

Thrombotic triad in microgravity.

Thrombosis research·2023
Same author

Identification of an Optimized Receptor-Binding Domain Subunit Vaccine against SARS-CoV-2.

Journal of immunology (Baltimore, Md. : 1950)·2023
Same author

Correction of haemorrhagic shock-associated coagulopathy and impaired haemostasis by plasma, prothrombin complex concentrates or an activated protein C-targeted DNA aptamer in mice.

Scientific reports·2023
Same author

Coagulation and complement: Key innate defense participants in a seamless web.

Frontiers in immunology·2022
Same journal

Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.

Research and practice in thrombosis and haemostasis·2026
Same journal

Thromboembolic ischemic stroke induces neutrophil recruitment and matrix metalloproteinase-9 release to enhance ischemic brain injury.

Research and practice in thrombosis and haemostasis·2026
Same journal

Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding.

Research and practice in thrombosis and haemostasis·2026
Same journal

Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.

Research and practice in thrombosis and haemostasis·2026
Same journal

Venous thromboembolic and bleeding risk in population with obesity hospitalized for an acute medical illness receiving enoxaparin for thromboprophylaxis.

Research and practice in thrombosis and haemostasis·2026
Same journal

Identifying risk factors for venous thromboembolism in medical inpatients: a systematic review and meta-analysis.

Research and practice in thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: Dec 14, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Antiviral anticoagulation.

Edward L G Pryzdial1,2, Michael R Sutherland1,2, Bryan H Lin1,2

  • 1Center for Innovation Canadian Blood Services Vancouver BC Canada.

Research and Practice in Thrombosis and Haemostasis
|July 21, 2020
PubMed
Summary
This summary is machine-generated.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, characterized by thrombophilia and inflammation. Aberrant tissue factor (TF) expression may underlie these symptoms, suggesting TF/FVIIa/FXa complex as a therapeutic target.

Keywords:
COVID‐19coagulationherpes simplex virusinflammationprotease‐activated receptortissue factor

More Related Videos

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

8.2K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Related Experiment Videos

Last Updated: Dec 14, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

8.2K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Area of Science:

  • Virology
  • Hematology
  • Immunology

Background:

  • COVID-19 presents with unique thrombophilia and severe inflammation.
  • Tissue factor (TF) plays a crucial role in initiating blood clotting and inflammation.
  • Viruses, including herpes simplex virus type 1 (HSV1), can harbor surface TF, influencing disease pathology.

Purpose of the Study:

  • To investigate the role of tissue factor (TF) in SARS-CoV-2 pathogenesis.
  • To explore the potential of targeting the TF/FVIIa/FXa complex as a therapeutic strategy for COVID-19.

Main Methods:

  • Review of existing literature on viral infections, TF expression, and coagulopathy.
  • Analysis of the proposed mechanism of TF integration into viral envelopes.
  • Examination of the therapeutic potential of anticoagulants targeting the TF pathway.

Main Results:

  • SARS-CoV-2 replicates in TF-expressing cells, suggesting TF may be involved in COVID-19.
  • Envelope TF is essential for HSV1 infection in mice, and apixaban showed antiviral efficacy.
  • The TF/FVIIa/FXa complex is implicated in both clotting and inflammatory aspects of COVID-19.

Conclusions:

  • COVID-19 may be a 'TFopathy,' a disease driven by aberrant tissue factor activity.
  • Targeting the TF/FVIIa/FXa complex presents a promising therapeutic avenue for managing COVID-19 symptoms.